Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray is formulated as a white, uniform metered-spray suspension for intranasal administration. It is a fixed dose combination product containing an antihistamine (H1 receptor antagonist) and a corticosteroid as active ingredients.
Dymista Nasal Spray is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief.
Clinical Trials Related to Dymista (Azelastine / Fluticasone)
Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis [Recruiting]
Dymista, a combined product containing the antihistamine azelastine and the intranasal
steroid fluticasone, provides superior clinical efficacy to both fluticasone propionate and
azelastine hydrochloride in the treatment of seasonal allergic rhinitis. The superiority of
efficacy not only occurs at the initiation of treatment, but persists for its duration. The
mechanism underlying the superior efficacy of Dymista is not known. This trial focuses on
examining the effects of Dymista on the dynamics of the allergic response in man using nasal
provocation with antigen. The investigators will study the relationship between symptoms,
physiology, cells and mediators.
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR) [Completed]
The purpose of this study is to determine if Dymista nasal spray is better and safer than
placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis [Completed]
This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with
AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) [Recruiting]
Comparative analysis of the efficacy of intranasal MP29-02 (a novel formulation of
azelastine and FP) has already been conducted in patients with moderate-to-severe seasonal
AR. The combination formulation appeared to be superior in these patients with better
symptomatic relief. However, objective analysis of the effect of this treatment on nasal
mediators and/or nasal hyperreactivity has not yet been performed and would help in
understanding the additional benefit of the combination treatment over monotherapy with
Page last updated: 2013-10-31